Spironolactone might be a desirable immunologic and hormonal intervention in autism spectrum disorders

Medical Hypotheses

Volumn 68, Issue 5, 2007, Pages 979-987

  Bradstreet, James Jeffrey ^a   Smith, Scott ^a   Granpeesheh, Doreen ^b   El Dahr, Jane M ^c   Rossignol, Daniel ^d  

^a FLORIDA HOSPITAL   (United States)

^b Center for Autism and Related Disorders   (United States)

^c TULANE UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^d UNIVERSITY OF VIRGINIA   (United States)

Author keywords

Androgen; Anti androgen; Anti inflammatory; Autism; Autism spectrum disorders; Immune dysregulation; Inflammation; Neuroglia; Neuroinflammation; Spironolactone; Testosterone

Indexed keywords

ALDOSTERONE ANTAGONIST; ANTIANDROGEN; CD4 ANTIGEN; CD8 ANTIGEN; CYPROTERONE ACETATE; FINASTERIDE; IMMUNOGLOBULIN; PENTOXIFYLLINE; PHOSPHODIESTERASE INHIBITOR; POTASSIUM SPARING DIURETIC AGENT; PRASTERONE; PRASTERONE SULFATE; SPIRONOLACTONE; TESTOSTERONE; TRANSFER FACTOR; TUMOR NECROSIS FACTOR ALPHA;

ABSENCE OF SIDE EFFECTS; ADULT; ALDOSTERONE RELEASE; ANDROGEN RELEASE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; AUTISM; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CHILD; DIGESTIVE SYSTEM INFLAMMATION; DIURESIS; DRUG SAFETY; GLIA; HUMAN; HYPERACTIVITY; IMMUNE DYSREGULATION; IMMUNOMODULATION; IRRITABILITY; LETHARGY; MAJOR CLINICAL STUDY; NERVE CELL EXCITABILITY; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SPEECH DISORDER; STEREOTYPY;

ALDOSTERONE ANTAGONISTS; ANDROGEN ANTAGONISTS; AUTISTIC DISORDER; CHILD; HUMANS; MODELS, IMMUNOLOGICAL; SPIRONOLACTONE;

EID: 33847170648     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2006.10.015     Document Type: Article

References (64)

1. Kanner L. Autistic disturbances of affective contact. Nervous Child 2 (1943) 217-250
2. Baird G., Cass H., and Slonims V. Diagnosis of autism. BMJ 327 7413 (2003) 488-493
3. Baird G., Simonoff E., Pickles A., et al. Prevalence of disorders of the autism spectrum in a population cohort of children in South Thames: the Special Needs and Autism Project (SNAP). Lancet 368 9531 (2006) 210-215
4. Schieve LA, Rice C, Boyle C, Visser SN, Blumberg SJ. Mental Health in the United States: Parental Report of Diagnosed Autism in Children Aged 4-17 Years - United States, 2003-2004. Morbidity and Mortality Weekly Report 2006;55(17):481-6.
5. Tordjman S., Ferrari P., Sulmont V., Duyme M., and Roubertoux P. Androgenic activity in autism. Am J Psychiatr 154 11 (1997) 1626-1627
6. Knickmeyer R., Baron-Cohen S., Raggatt P., and Taylor K. Foetal testosterone, social relationships, and restricted interests in children. J Child Psychol Psychiatr 46 2 (2005) 198-210
7. Geier D.A., and Geier M.R. A clinical and laboratory evaluation of methionine cycle-transsulfuration and androgen pathway markers in children with autistic disorders. Horm Res 66 4 (2006) 182-188
8. Stubbs E.G. Autistic children exhibit undetectable hemagglutination-inhibition antibody titers despite previous rubella vaccination. J Autism Child Schizophr 6 3 (1976) 269-274
9. Stubbs E.G., and Crawford M.L. Depressed lymphocyte responsiveness in autistic children. J Autism Child Schizophr 7 1 (1977) 49-55
10. Weizman A., Weizman R., Szekely G.A., Wijsenbeek H., and Livni E. Abnormal immune response to brain tissue antigen in the syndrome of autism. Am J Psychiatr 139 11 (1982) 1462-1465
11. Warren R.P., Margaretten N.C., Pace N.C., and Foster A. Immune abnormalities in patients with autism. J Autism Dev Disord 16 2 (1986) 189-197
12. Warren R.P., Foster A., and Margaretten N.C. Reduced natural killer cell activity in autism. J Am Acad Child Adolesc Psychiatr 26 3 (1987) 333-335
13. Ferrari P., Marescot M.R., Moulias R., et al. Immune status in infantile autism. Correlation between the immune status, autistic symptoms and levels of serotonin [French]. Encephale 14 5 (1988) 339-344
14. Warren R.P., Yonk L.J., Burger R.A., et al. Deficiency of suppressor-inducer (CD4+CD45RA+) T cells in autism. Immunol Invest 19 3 (1990) 245-251
15. Francesetti G., Gecele M., and Meluzzi A. Psychoimmunology. II. The neuroendocrine system and the immune system in autism and schizophrenia [Italian]. Minerva Psychiatr 32 2 (1991) 75-82
16. Singh V.K., Warren R.P., Odell J.D., and Cole P. Changes of soluble interleukin-2, interleukin-2 receptor, T8 antigen, and interleukin-1 in the serum of autistic children. Clin Immunol Immunopathol 61 3 (1991) 448-455
17. Warren R.P., Yonk J., Burger R.W., Odell D., and Warren W.L. DR-positive T cells in autism: association with decreased plasma levels of the complement C4B protein. Neuropsychobiology 31 2 (1995) 53-57
18. Scifo R., Cioni M., Nicolosi A., et al. Opioid-immune interactions in autism: behavioural and immunological assessment during a double-blind treatment with naltrexone. Ann Ist Super Sanita 32 3 (1996) 351-359
19. Singh V.K., Warren R., Averett R., and Ghaziuddin M. Circulating autoantibodies to neuronal and glial filament protein in autism. Pediatr Neurol 17 1 (1997) 88-90
20. Messahel S., Pheasant A.E., Pall H., Ahmed-Choudhury J., Sungum-Paliwal R.S., and Vostanis P. Urinary levels of neopterin and biopterin in autism. Neurosci Lett 241 1 (1998) 17-20
21. Connolly A.M., Chez M.G., Pestronk A., Arnold S.T., Mehta S., and Deuel R.K. Serum autoantibodies to brain in Landau-Kleffner variant, autism, and other neurologic disorders. J Pediatr 134 5 (1999) 607-613
22. Connolly A.M., Chez M., Streif E.M., et al. Brain-derived neurotrophic factor and autoantibodies to neural antigens in sera of children with autistic spectrum disorders, Landau-Kleffner syndrome, and epilepsy. Biol Psychiatr 59 4 (2006) 354-363
23. Molloy C.A., Morrow A.L., Meinzen-Derr J., et al. Elevated cytokine levels in children with autism spectrum disorder. J Neuroimmunol 172 1-2 (2006) 198-205
24. Jyonouchi H., Sun S., and Le H. Proinflammatory and regulatory cytokine production associated with innate and adaptive immune responses in children with autism spectrum disorders and developmental regression. J Neuroimmunol 120 1-2 (2001) 170-179
25. Jyonouchi H., Geng L., Ruby A., and Zimmerman-Bier B. Dysregulated innate immune responses in young children with autism spectrum disorders: their relationship to gastrointestinal symptoms and dietary intervention. Neuropsychobiology 51 2 (2005) 77-85
26. Vojdani A., O'Bryan T., Green J.A., et al. Immune response to dietary proteins, gliadin and cerebellar peptides in children with autism. Nutr Neurosci 7 3 (2004) 151-161
27. Wakefield A.J., Murch S.H., Anthony A., et al. Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children. Lancet 351 9103 (1998) 637-641
28. Horvath K., Papadimitriou J.C., Rabsztyn A., Drachenberg C., and Tildon J.T. Gastrointestinal abnormalities in children with autistic disorder. J Pediatr 135 5 (1999) 559-563
29. Murch S.H., Anthony A., Casson D.H., et al. Retraction of an interpretation. Lancet 363 9411 (2004) 750
30. Balzola F., Barbon V., Repici A., et al. Panenteric IBD-like disease in a patient with regressive autism shown for the first time by the wireless capsule enteroscopy: another piece in the jigsaw of this gut-brain syndrome?. Am J Gastroenterol 100 4 (2005) 979-981
31. Chauhan A, Mehta PD, Cohen IL, Barshatzky M, Brown T, Chauhan V. Increased serum complement C3/C4 and alpha-1-antichymotrypsin levels in autism. PS3.19, IMFAR. http://conferences.ucdavis.edu/imfar/IMFAR_2006_abstract_book.pdf. June, 2006 [accessed 10/2/06].
32. Gillberg C. Autism spectrum conditions: what are the associated problems and what can they tell us? IMFAR. http://conferences.ucdavis.edu/imfar/IMFAR_2006_abstract_book.pdf. June, 2006 [accessed 10/2/06].
33. Ashwood P., Anthony A., Torrente F., and Wakefield A.J. Spontaneous mucosal lymphocyte cytokine profiles in children with autism and gastrointestinal symptoms: mucosal immune activation and reduced counter regulatory Interleukin-10. J Clin Immunol 24 6 (2004) 664-673
34. Vargas D.L., Nascimbene C., Krishnan C., Zimmerman A.W., and Pardo C.A. Neuroglial activation and neuroinflammation in the brain of patients with autism. Ann Neurol 57 1 (2005) 67-81
35. Zimmerman A.W., Jyonouchi H., Comi A.M., et al. Cerebrospinal fluid and serum markers of inflammation in autism. Pediatr Neurol 33 3 (2005) 195-201
36. Singer H.S., Morris C.M., Williams P.N., Yoon D.Y., Hong J.J., and Zimmerman A.W. Antibrain antibodies in children with autism and their unaffected siblings. J Neuroimmunol 178 1-2 (2006) 149-155
37. Gupta S., Aggarwal S., and Heads C. Dysregulated immune system in children with autism: beneficial effects of intravenous immune globulin on autistic characteristics. J Autism Dev Disord 26 4 (1996) 439-452
38. Oleske J. Another view of autism. UMDNJ Research 2004;5(1):22-23. http://www.umdnj.edu/research/publications/winter_04.pdf. [accessed 10/2/06].
39. O'Banion D., Armstrong B., Cummings R.A., and Stange J. Disruptive behavior: a dietary approach. J Autism Child Schizophr 8 3 (1978) 325-337
40. Lucarelli S., Frediani T., Zingoni A.M., et al. Food allergy and infantile autism. Panminerva Med 37 3 (1995) 137-141
41. Cade R., Privette M., Fregly M., et al. Autism and schizophrenia: intestinal disorders. Nutr Neurosci 2 (1999) 57-72
42. Knivbserg A.M., Reichelt K.L., Nodland M., and Hoien T. Autistic syndromes and diet: a four year follow-up study. Scand J Educat Res 39 (1995) 223-236
43. Gupta S. Immunological treatments for autism. J Autism Dev Disord 30 5 (2000) 475-479
44. Shenoy S., Arnold S., and Chatila T. Response to steroid therapy in autism secondary to autoimmune lymphoproliferative syndrome. J Pediatr 136 5 (2000) 682-687
45. Stefanatos G.A., Grover W., and Geller E. Case study: corticosteroid treatment of language regression in pervasive developmental disorder. J Am Acad Child Adolesc Psychiatr 34 (1995) 1107-1111
46. Chez M., Buchanan C., Loeffel M., et al. Practical treatment with pulse dose corticosteroids in pervasive developmental disorder or autistic patients with abnormal epileptiform sleep EEG and language delay. In: Milivovojelick P. (Ed). New developments in child neurology (1998), Monduzzi Editore, Bologna 695-698
47. Geier M.R., and Geier D.A. The potential importance of steroids in the treatment of autistic spectrum disorders and other disorders involving mercury toxicity. Med Hypotheses 64 5 (2005) 946-954
48. Geier M, Geier D. The biochemical basis for the treatment of autistic disorders: the androgen (Testosterone) - glutathione connection. http://www.autismone.org/download2006.cfm. May, 2006 [accessed 10/2/06].
49. Realmuto G.M., and Ruble L.A. Sexual behaviors in autism: problems of definition and management. J Autism Dev Disord 29 2 (1999) 121-127
50. Buck M.L. Clinical experience with spironolactone in pediatrics. Ann Pharmacother 39 5 (2005) 823-828
51. ® Pfizer Inc. http://www.pfizer.com/pfizer/download/uspi_aldactone.pdf [accessed 10/2/06].
52. Lumb G., Newberne P., Rust J.H., and Wagner B. Effects in animals of chronic administration of spironolactone - a review. J Environ Pathol Toxicol 1 5 (1978) 641-660
53. Bajusz E., and Jasmin G. Effect of aldactone, an antiminera-locorticoid steroid spironolactone, on inflammation. Rev Can Biol 20 (1961) 829-832
54. Miura R., Nakamura K., Miura D., et al. Anti-inflammatory effect of spironolactone on human peripheral blood mononuclear cells. J Pharmacol Sci 101 3 (2006) 256-259
55. Bendtzen K., Hansen P.R., and Rieneck K. The Spironolactone/Arthritis Study Group. Spironolactone inhibits production of proinflammatory cytokines, including tumour necrosis factor-alpha and interferon-gamma, and has potential in the treatment of arthritis. Clin Exp Immunol 134 1 (2003) 151-158
56. Takebayashi K., Matsumoto S., Aso Y., and Inukai T. Aldosterone blockade attenuates urinary monocyte chemoattractant protein-1 and oxidative stress in patients with type 2 diabetes complicated by diabetic nephropathy. J Clin Endocrinol Metab 91 6 (2006) 2214-2217
57. James S.J., Cutler P., Melnyk S., et al. Metabolic biomarkers of increased oxidative stress and impaired methylation capacity in children with autism. Am J Clin Nutr 80 6 (2004) 1611-1617
58. Farquhar C., Lee O., Toomath R., and Jepson R. Spironolactone versus placebo or in combination with steroids for hirsutism and/or acne. Cochrane Database Syst Rev 4 (2003) CD000194
59. Berardesca E., Gabba P., Ucci G., Borroni G., and Rabbiosi G. Topical spironolactone inhibits dihydrotestosterone receptors in human sebaceous glands: an autoradiographic study in subjects with acne vulgaris. Int J Tissue React 10 2 (1988) 115-119
60. Darendeliler F., Bas F., Balaban S., et al. Spironolactone therapy in hypertrichosis. Eur J Endocrinol 135 5 (1996) 604-608
61. Leschek E.W., Jones J., Barnes K.M., Hill S.C., and Cutler Jr. G.B. Six-year results of spironolactone and testolactone treatment of familial male-limited precocious puberty with addition of deslorelin after central puberty onset. J Clin Endocrinol Metab 84 1 (1999) 175-178
62. Doggrell S.A., and Brown L. The spironolactone renaissance. Expert Opin Inv Drug 10 5 (2001) 943-954
63. Aman M.G., Singh N.N., Stewart A.W., and Field C.J. Psychometric characteristics of the aberrant behavior checklist. Am J Ment Def 89 5 (1985) 492-502
64. Condouris K., Meyer E., and Tager-Flusberg H. The relationship between standardized measures of language and measures of spontaneous speech in children with autism. Am J Speech Lang Pathol 12 3 (2003) 349-358